Cutting Edge Research Group

1. Otsuka Pharmaceutical Development & Commercialization, Inc. $332,215 24 payments
2. AbbVie, Inc. $117,457 36 payments
3. Sunovion Pharmaceuticals Inc. $62,033 2 payments
4. Allergan Inc. $42,439 11 payments
5. Shire North American Group Inc $38,513 10 payments
6. ITI, Inc. $33,376 19 payments
7. Pfizer Inc. $22,090 25 payments
8. Eisai Inc. $19,489 2 payments
9. Teva Pharmaceuticals USA, Inc. $15,900 6 payments
10. Takeda Pharmaceuticals U.S.A., Inc. $13,202 3 payments

1. Pediatric Open-Label Extension Study $62,033 2 payments
2. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder $57,126 2 payments
3. A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Trial Evaluating the Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder (Trial 405-201-00013) $52,003 1 payment
4. A Study of the Change in Disease State and Safety of Oral Cariprazine Capsules in the Treatment of Depression in Pediatric Participants (10 to 17 Years of Age) With Bipolar I Disorder $47,269 11 payments
5. An Open-Label, 52-Week, Multicenter Trial Evaluating the Long-Term Safety and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder $43,277 2 payments
6. Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine $39,421 13 payments
7. A Long-Term, Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Flexible-Dose Brexpiprazole As Maintenance Treatment in Adolescent Patients With Schizophrenia $33,191 4 payments
8. A Phase 3, Multicenter, Open-Label Trial to Evaluate the Long Term Safety and Tolerability of Brexpiprazole (Opc-34712) in the Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder $32,395 3 payments
9. A 26-Week, Multicenter, Open-Label, Flexible-Dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia Or Bipolar I Disorder $28,433 7 payments
10. Iti-007-321 $26,701 17 payments

1. Other $5,616 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.